Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis
Author:
- 18 January 2019
- journal article
- research article
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 12 (2) , 95-99
Abstract
Introduction: Hereditary transthyretin-mediated amyloidosis is caused by a mutation in transthyretin (TTR) gene resulting in misfolded TTR protein accumulating as amyloid fibrils. Patisiran is a lipid nanoparticle formulation of ribonucleic acid interference (RNAi), which can reduce the production of TTR. Areas covered: In this review, the chemical property, mechanism of action, pharmacokinetics, clinical efficacy, and safety of patisiran were introduced. Expert Commentary: Patisiran offers a new treatment option for patients with hereditary transthyretin-mediated amyloidosis. Patisiran can significantly reduce the TTR level and improve patient’s neuropathy and quality of life. The common adverse reactions were upper respiratory tract infections and infusion-related reactions.Keywords
Funding Information
- was not funded
This publication has 37 references indexed in Scilit:
- Family dynamics in transthyretin‐related familial amyloid polyneuropathy Val30Met: Does genetic risk affect family functioning?Clinical Genetics, 2018
- Oligonucleotide Drugs for Transthyretin AmyloidosisNew England Journal of Medicine, 2018
- Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trialAmyloid, 2018
- Inhibition of the Amyloidogenesis of Transthyretin by Natural Products and Synthetic CompoundsBiological and Pharmaceutical Bulletin, 2018
- Evolving landscape in the management of transthyretin amyloidosisAnnals of Medicine, 2015
- Novel Drugs Targeting Transthyretin AmyloidosisCurrent Heart Failure Reports, 2014
- Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 2013
- Cardiac transthyretin amyloidosisHeart, 2012
- Familial amyloid polyneuropathyThe Lancet Neurology, 2011
- Type I (Transthyretin Met30) Familial Amyloid Polyneuropathy in JapanArchives of Neurology, 2002